You are here: Industry Insights > VITROS

News List

Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test prnasia
August 05, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, today announced its qualitative COVID-19 Total N antibody test received U.S. Food and Drug Administration EUA.
Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu prnasia
July 23, 2021
Ortho Clinical Diagnostics announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho's VITROS® Critical Care menu, is now available in EU Countries, U.K. and several ASPAC and LATAM countries.*
Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific prnasia
July 08, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play, in-vitro diagnostics (IVD) companies, announced its distribution agreement with Thermo Fisher Scientific™ to provide and support MAS™ Quality Controls and LabLink xL™ Quality Assurance ...
Ortho Clinical Diagnostics Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A Nucleocapsid Antibody Test to Help Differentiate Cause of Antibody Response prnasia
May 24, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced the launch of the first quantitative COVID-19 IgG antibody test in addition to a total COVID-19 nucleocapsid antibody test.
Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark prnewswire
May 06, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced its quantitative COVID-19 IgG antibody test achieved CE Mark.
Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of Mass-Scale Testing prnasia
April 27, 2021
Ortho Clinical Diagnostics has been recognized with a prestigious silver 2021 Edison Award for its VITROS® COVID-19 testing solutions, helping labs meet demands of the pandemic with reliable mass-scale testing options.
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media prnasia
April 14, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced it received CE Marking for its VITROS® SARS-CoV-2 Antigen Test, initially launched in October 2020.
Ortho Announces Plans to Accelerate COVID-19 Antigen and Antibody Test Development Through New Contract with BARDA and the Department of Defense prnasia
April 01, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play IVD companies, today announced that through its continued partnership with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Defense ...
Ortho's New COVID-19 Total, IgG Antibody Tests Receive CE Mark americanpharmaceuticalreview
March 16, 2021
Ortho Clinical Diagnostics announced that its new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay received CE Mark for the qualitative and semi-quantitative detection of COVID-19 antibodies.
Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative prnewswire
March 09, 2021
Ortho Clinical Diagnostics announced that its new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay received CE Mark for the qualitative and semi-quantitative detection of COVID-19 antibodies.

Previous page 1 2 Next page